Chromosome 9 alterations are the most frequently encountered cytologic anomalies in urothelial carcinoma (UC). We previously screened 139 low-stage UCs for loss of heterozygosity on chromosome 9, and identified five distinct regions likely to harbour tumour-suppressor genes. The present study focused on deletion mapping in the 9q22 region with 11 additional microsatellite markers. New deletions in the 9q22 region were found in five tumours. Deletion mapping allowed us to identify a 0.5 CM common minimal region of deletion between markers D9S280 and D9S1809, encompassing PATCHED (PTC), a gene identified as a tumour suppressor in basal cell carcinoma and in medulloblastoma. A marker located in the first intron of this gene showed the highest percentage of deletion (45%). cDNA sequencing in 15 tumours with deletion of PTC showed no mutation in the remaining allele. However, average expression of PTC mRNA measured by semiquantitative RT-PCR was significantly decreased in tumours with LOH in the 9q22 region, compared to normal urothelium (P ¼ 0.04), while it showed marked fluctuations in tumours without deletion. Our results suggest that the PTC gene is a putative suppressor at the 9q22 locus and that haploinsufficiency of this gene may be an early event in the development of papillary bladder tumours.
Chromosome 9 alterations are the most frequently encountered cytologic anomalies in urothelial carcinoma (UC). We previously screened 139 low-stage UCs for loss of heterozygosity on chromosome 9, and identified five distinct regions likely to harbour tumour-suppressor genes. The present study focused on deletion mapping in the 9q22 region with 11 additional microsatellite markers. New deletions in the 9q22 region were found in five tumours. Deletion mapping allowed us to identify a 0.5 CM common minimal region of deletion between markers D9S280 and D9S1809, encompassing PATCHED (PTC), a gene identified as a tumour suppressor in basal cell carcinoma and in medulloblastoma. A marker located in the first intron of this gene showed the highest percentage of deletion (45%). cDNA sequencing in 15 tumours with deletion of PTC showed no mutation in the remaining allele. However, average expression of PTC mRNA measured by semiquantitative RT-PCR was significantly decreased in tumours with LOH in the 9q22 region, compared to normal urothelium (P ¼ 0.04), while it showed marked fluctuations in tumours without deletion. Our results suggest that the PTC gene is a putative suppressor at the 9q22 locus and that haploinsufficiency of this gene may be an early event in the development of papillary bladder tumours. Oncogene (2003 Oncogene ( ) 22, 2967 Oncogene ( -2971 Oncogene ( . doi:10.1038 Keywords: chromosome 9; LOH; bladder cancer tumour-suppressor gene; PATCHED gene; RT-PCR Cytogenetic studies of urothelial carcinomas (UCs) have revealed a variety of chromosomal anomalies (Vanni et al., 1988) . However, alterations of chromosome 9 are the most frequently observed in tumours of all grades and stages and often the only alteration in many lowstage lesions (Cairns et al., 1993) , suggesting that inactivation of a tumour-suppressor gene (TSG) on chromosome 9 may represent an early event in bladder carcinogenesis. Attempts to locate critical regions of deletion that may contain putative TSGs were hampered by the high frequency of chromosome 9 monosomy.
When present, interstitial deletions were often large (Cairns et al., 1993) .
In a previous study, we screened 139 initial superficial (Ta, T1) UCs for loss of heterozygosity (LOH) of 28 microsatellite markers spanning chromosome 9 (Simoneau et al., 1999) . Apparent monosomy was rare and a relatively high number of tumours with interstitial deletions was observed. This allowed us to identify five putative TSG loci: two were newly described, 9q22 and 9q31; the three others, 9p21, 9q33 and 9q34, have been reported in other studies, and putative TSGs in these regions have been proposed (Cairns et al., 1994; Tanaka et al., 1995; Habuchi et al., 1998; Hornigold et al., 1999) . Evidence for the implication of the 9q22 region in UC was also suggested. A microcell fusion study in which normal human chromosome 9 was transferred into a bladder cancer cell line suggested the presence of at least three functional TSG loci on 9q, including 9q22 (Wu et al., 1996) . The evolution of alterations on chromosome 9 was also studied in relation to the progression of UCs by using superimposed histologic and genetic mapping in cystectomy specimens (Czerniak et al., 1999) . A clonal relation was found among multiple samples from the same patient, and several regions on 9q, including 9q22, were suggested to contain critical genes for the development of UC. Recently, we showed that 9q22 was one of three regions on 9q (with 9q33 and 9q34) where deletion was associated with a high risk of tumour recurrence (Simoneau et al., 2000) . These observations suggest the presence of an important TSG at the 9q22 locus that is involved in UC.
In the present study, we attempted to better define the minimal region of deletion at 9q22, by analysing LOH of 11 additional microsatellite markers, evenly distributed along the 9q22 region, on the 139 previously analysed superficial UCs (Simoneau et al., 1999) . The most frequently deleted marker (45%) was located in the first intron of PATCHED (PTC), a human ortholog of the drosophila patched gene (Xie et al., 1997) (Table 1 ). Figure 1 shows deletion mapping for 32 9q microsatellite markers, 11 from this study and 21 from the previous one, for tumours with partial deletions in the 9q22 region. Two tumours with no deletion at any marker in our first analysis, were now shown to present LOH at the 9q22 locus (tumours 69 for the PTC marker only and 97 for all informative new markers except D9S1796) (Figure 1 ). Three other tumours, with only one LOH at another locus in the first study (tumours 102 at 9q13, 47 at 9p21 and 120 at 9q33), showed additional LOH of the PTC marker (sole additional loss in tumours 120 and 47) (Figure 1) . Combined deletion mapping analysis demonstrated a common minimal region of deletion (approximately 0.5 CM of extent) between markers D9S280 and D9S1809 (Figure 1 ). The LDB database lists two genes mapping in this region. One is the Fanconi Anemia Complementation Group C (FACC) gene, coding for a 558 amino acid protein (Gibson et al., 1993 ). An indirect role in repair of DNA damage has been attributed to FACC (Yamashita et al., 1994) and a link to the cell cycle was established (Kupfer et al., 1997) . However, to our knowledge, no mutation of the FACC gene has been associated with cancer. A second gene located in the 9q22 minimal region of deletion is the PTC gene (Hahn et al., 1996; Johnson et al., 1996) . First described in the drosophila, PTC is part of an important pathway involved in developmental patterning (Chen and Struhl, 1996; Goodrich et al., 1996; Wicking et al., 1999) . According to current hypotheses, the PTC protein acts as a repressor of the pathway that is mediated through binding of the secreted protein Sonic Hedgehog (SHH). An additional membrane protein, smoothened (SMO), is required to carry out signalling (Marigo et al., 1996; Stone et al., 1996) , and activation of the pathway translates into transcriptional activation of various genes, including PTC itself. The high degree of conservation of this pathway between flies and vertebrates (Hahn et al., 1996) testifies to its importance.
The Knudson 'two-hit' theory of carcinogenesis (Knudson, 1993) proposes inactivation of TSGs through deletion of one copy of the gene and inactivation of the Figure 1 Mapping of LOH for 9q22 microsatellite markers was carried out as described (Zhang et al., 1992; Simoneau et al., 1999) on 139 superficial UCs. Combined data from this study (11 markers in bold characters) and a previous one (Simoneau et al., 1999) are shown for tumours with interstitial deletions. Ten of the 11 new 9q22 markers are listed in the LDB database (http:// cedar.genetics.soton.ac.uk/public_html/). The 11th one was the PTC marker. LOH was defined as a X50% decrease in intensity of the PCR product signal of an allele in the tumour, compared to normal blood DNA
The PATCHED locus in superficial bladder cancer TO Aboulkassim et al other through mutation or other means. To search for the presence of PTC mutations, the PTC cDNA was sequenced in 15 bladder tumours, which had lost one PTC allele. No mutations were found. However, polymorphisms were detected in three tumours: a C-T transition at nucleotide 1674 (exon 12) ( Figure 2 ) and at nucleotide 4129 (exon 22) and a G-A transition at nucleotide 3315 (exon 20). To detect whether PTC LOH had an impact on gene expression, analysis of PTC mRNA expression in 11 tumours with LOH of the PTC marker, 10 tumours with no LOH of any analysed marker, and four normal urothelial tissues was carried out (Figure 3) . PTC mRNA expression was found to be reduced in most (10/11) tumours with PTC LOH and the average expression in these tumours decreased significantly when compared to normal bladder tissues (P ¼ 0.04 w 2 test) (Figure 3) . On the other hand, expression levels of PTC mRNA varied considerably among tumours with no LOH in the 9q22 region, with PTC expression increased in four tumours (tumours c, e, i and j) and decreased in five tumours (tumours a, b, d, f and g). However, when compared to normal urothelium, no significant variation was observed in the average expression level in tumours without PTC LOH (P ¼ 0.46 w 2 test). It was recently reported that loss of one copy of a gene without any alteration in the remaining wild-type allele, a phenomenon referred to as haploinsufficiency, may be sufficient to promote cancer in many instances. Such is the case with the PTEN gene in solid renal cell carcinomas (Velickovic et al., 2002) , SMAD4 in gastric cancers (Xu et al., 2000; Maurice et al., 2001 ) and p27 in various other cancers (Fero et al., 1998; Philipp-Staheli et al., 2001) . Our data raise the possibility that haploinsufficiency of PTC may be involved in early UC, at least in tumours with LOH of the PTC marker. In most tumours without PTC LOH, although average expression is comparable to normal urothelium, expression is either increased or decreased, suggesting the presence of abnormalities in the PTC/SHH pathway. The markedly increased expression in four tumours suggests the possibility of gene amplification. To our knowledge, such an occurrence has not been reported for the PTC gene. On the other hand, increased PTC expression has been reported in cancers such as BCCs and medulloblastomas even in the presence of PTC LOH (Wicking et al., 1999; Zurawel et al., 2000) . Various studies have suggested that any disruption in the equilibrium between PTC, SHH and SMO can lead to tumour formation. Rapid induction of BCCs was observed in transgenic mice overexpressing Shh (Oro et al., 1997) . Overexpression of SMO was also found in most BCCs (Kallassy et al., 1997) while haploinsufficiency of PTC was shown to induce medulloblastoma (Zurawel et al., 2000) and rhabdomyosarcoma in mice (Calzada-Wack et al., 2002) .
Mutations of the human PTC gene have been associated with the nevoid basal cell carcinoma (BCC) syndrome, an autosomal dominant disorder characterized by developmental abnormalities (Gorlin, 1987) . Several tumours occur in this syndrome, the most frequent being BCC, where a role as TSG has been firmly established for PTC, in both the sporadic and familial forms Hahn et al., 1996; Johnson et al., 1996; Bale and Yu, 2001 ). Interestingly, superficial papillary UCs and BCCs have some similarities. Both present persistent local growth but rarely metastasize. No premalignant step is clearly identifiable in either tumour, and the pathogenesis of both is frequently associated with environmental causes. BCC may be induced by exposure to ultraviolet or ionizing The PATCHED locus in superficial bladder cancer TO Aboulkassim et al radiation, while chemical carcinogens derived from environmental contaminants and concentrated in urine promote bladder carcinogenesis. Furthermore, as we found for UCs, LOH is observed in close to 50% of BCCs (Hahn et al., 1996) . It is thus reasonable to suspect that similar pathways may be altered in both of these neoplasias. However, contrary to our data, PTC mutations are found in 12-38% of sporadic BCCs and overexpression of PTC is observed in these tumours (Wicking et al., 1999) . The expression of PTC mRNA in normal urothelium, the absence of PTC mutations and the decreased expression of PTC mRNA in UCs, all argue for a different regulation of the PTC/SHH pathway in bladder than in skin.
Together, these data suggest that alteration of the PTC/SHH signalling pathway may be involved in the genesis of superficial papillary bladder cancer and that altered expression, through haploinsufficiency or otherwise, of the PTC gene might be a cause by which this process is achieved. Moreover, we recently obtained evidence that heterozygous Ptc mutant mice develop UC more rapidly than their wild-type littermates when exposed to chemical carcinogenesis (submitted). Analysis of the expression of other members of the pathway and especially of its downstream transcription effectors should provide a more complete idea of the alterations involved in the PTC/SHH pathway in UC. RNA was purified from 11 bladder tumours with PTC LOH, 10 tumours without LOH and four normal urotheliums using TRIZOL (Gibco-BRL). Semiquantitative RT-PCR was carried out using MMLV-reverse transcriptase followed by PCR with primers PTC164R and F yielding a 658 bp PTC fragment and 5 0 -TGGAGTCCACTGGCGTCTTCAC-3 0 and 5 0 -CATGAGGTCCAC-CACCCTGTTG-3 0 , yielding a 697 bp glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) fragment as a control. PCR was carried out using 1 U Taq DNA polymerase (Gibco-BRL), 2.5 mm MgCl 2 and 2.5 mCi [a-32 P]dCTP (3000 Ci/mmol) (NEN Life Science Products, Boston, MA, USA). PCR was performed for 27 cycles (GAPDH) or 30 cycles (PTC), both at an annealing temperature of 551C. PCR products were separated on a 6% acrylamide gel, and autoradiograms were scanned by phosphor imager (Storm 860, Molecular Dynamics, Sunnyvale, CA, USA). A ratio between PTC and GAPDH signal was calculated for each sample. Decrease or increase 450% of PTC/GAPDH ratio for tumours relative to average normal urothelium were considered as decrease or increase in PTC expression, respectively. (a) Electrophoretic gel; (b) histogram showing PTC/GAPDH ratios
